Abstract:Objective: Efficacy and tolerability of nifedipine gastrointestinal therapeutic system (GITS) 60 mg once daily (QD) in uncontrolled blood pressure (BP) is not completely explored in China. Therefore, we studied the efficacy and tolerability of nifedipine GITS 60 mg in Chinese hypertensive patients inadequately controlled with prior monotherapy. Design and method: This single-arm phase-4 study (NCT02413515) enrolled 278 hypertensive adults from 13 centers in China, in whom BP was uncontrolled after 4-weeks of antihypertensive monotherapy. The patients received oral nifedipine GITS 60 mg QD for 8-consecutive weeks. Primary endpoint was mean sitting systolic BP control rate (MSSBP; <130 mmHg for subjects with diabetes (DM) and <140 mmHg for others) at 8-weeks. Secondary endpoints included change in MSSBP and mean sitting diastolic BP (MSDBP), 24-h SBP and DBP reduction measured by 24 hour ABPM, and safety of nifedipine GITS 60 mg. Results: A total of 269 patients (mean age 55 ± 8.21 years, 62.8% males, 28.3% with DM) were included for efficacy and 278 for safety analysis. At week 8, overall MSSBP control rate was 64.7%. From baseline to 8-weeks, decrease in MSSBP and MSDBP was −15.2 ± 11.37 mmHg (147.9 ± 6.87 mmHg to 132.7 ± 11.82 mmHg) and −6.4 ± 7.87 mmHg (89.1 ± 7.13 mmHg to 82.7 ± 8.04), respectively (Table 1). The control rate was lower in patients with DM From baseline to 8-weeks, mean 24-h SBP was decreased from 138.5 ± 12.78 mmHg to 131.6 ± 12.29 mmHg (diff. −6.9 ± 11.30 mmHg, 95% CI −8.29, −5.56) and mean 24-h DBP was decreased from 86.4 ± 9.32 mmHg to 82.5 ± 9.12 mmHg (diff. −3.9 ± 7.63 mmHg, 95% CI −9.47, −6.42). Fifty (18%) cases of adverse events (AEs) and 25 (9%) cases of peripheral edema were reported. No drug related serious AEs and deaths occurred during the study.Conclusions: Nifedipine GITS 60 mg QD further improved control rate of MSSBP and MSDBP and was well tolerated in Chinese patients previously treated with standard dosage of antihypertensive monotherapy.

Short-term effectiveness and safety of Compound Anti-Hypertensive Tablets (No.0) in patients with primary hypertension

Compound anti-hypertensive tablets (No.0) for primary hypertension:a systematic review

THE EFFICACY AND SAFETY OF COMPOUND ANTI-HYPERTENSIVE TABLETS (NO.0) IN PATIENTS WITH ELDERLY ISOLATED SYSTOLIC HYPERTENSION

[Study on the Compliance of Antihypertensive Drugs in Patients with Hypertension].

Study on the long-term efficacy and safety of medicine named 'Beijing Hypertensive No. 0' in patients with primary hypertension]

The Effects of Compound Antihypertensive Tablets No.0 (HTDR) on Serum Potassium, Serum Sodium and Uric Acid in Hypertension Patients in Community

Long-term Efficacy and Safety of Beijing Hypotensive No.0 in Patients with Mild to Moderate Essential Hypertension

Clinical Study of Olmesartan/hydrochlorothiazide Compound Tablet in Mild to Moderate Essential Hypertensive Patients Who Did Not Reach Goal with Olmesartan

[A Randomized, Double-Blind, Double-Dummy Study Comparing a Fixed Dose Combination of Telmisartan 80 Mg Plus Hydrochlorothiazide 12.5 Mg to Telmisartan 80 Mg in Chinese Hypertensive Patients Who Failed to Respond Adequately to Telmisartan 80 Mg].

Efficacy and Safety of the Compound of Candesartan Cilexetial and Hydrochlorothiazide in Patients with Essential Hypertension

Effects of Atenolol and Diltiazem-Sr on Quality of Life in the Hypertensive Patients

Efficacy and Safety of Olmesartan Medoxomil-Amlodipine Besylate Tablet in Chinese Patients with Essential Hypertension: A Prospective, Single-Arm, Multi-Center, Real-World Study

Effects of Compound Hypotensive Tablets Administered at Different Time Points on Pressure Rhythm and 24-Hour Ambulatory Blood Pressure in Patients with Non-dipper Essential Hypertension

Comparison of Beijing Anti-hypertension 0 and Amlodiping in Treatment Essential Hypertension

Influence of Anti-hypertension No.0 on Depression in Treatment of Hypertension

Cost-effectiveness analysis on compound anti-hypertensive tablets for primary hypertension

Effects of Compound Valsartan in Patients with Mild to Moderate Essential Hypertension

Effects and safety of mild and moderate primary hypertension treated with olmesartan medoxomil tablet

The Clinical Efficacy and Safety of Valsartan in Treatment of Patients with Essential Hypertensive

[PP.02.03] EFFICACY AND TOLERABILITY OF NIFEDIPINE GASTROINTESTINAL THERAPEUTIC SYTEM 60MG IN CHINESE PATIENTS WITH UNCONTROLLED HYPERTENSION

A13979 Efficacy and Safety of Compound-Reserpine-triamterene Tabletsin Treatment to Non-Dipper Hypertension in Elderly